alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 31.1****NATIONAL INTERSTATE CORPORATION****SARBANES-OXLEY SECTION 302(a) CERTIFICATIONS**I, Alan R. Spachman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of National Interstate Corporation;  2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect to theperiod covered by this report;  3. Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periodspresented in this report;  4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, to ensurethat material information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;  b. Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness ofthe disclosure controls and procedures as of the end of the period covered by thisreport based on such evaluation; and  c. Disclosed in this report any change in the registrant’s internal controlover financial reporting that occurred during the registrant’s most recent fiscalquarter that has materially affected, or is reasonably likely to materially affect,the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to the registrant’sauditors and the audit committee of registrant’s board of directors (or persons performingthe equivalent functions): a. All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonably likelyto adversely affect the registrant’s ability to record, process, summarize andreport financial information; and  b. Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal control overfinancial reporting.August 15, 2005   /s/ Alan R. Spachman            Alan R. Spachman            Chairman of the Board and President            (Principal Executive Officer)  
24
Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 1 of 12 PageID 66
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 2 of 12 PageID 67
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 3 of 12 PageID 68
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 4 of 12 PageID 69
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 5 of 12 PageID 70
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 6 of 12 PageID 71
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 7 of 12 PageID 72
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 8 of 12 PageID 73
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 9 of 12 PageID 74
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 10 of 12 PageID 75
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 11 of 12 PageID 76
 

 Case 5:05-cv-00078-C Document 15 Filed 12/19/05 Page 12 of 12 PageID 77
Exhibit 32.1



Certification of the Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002



In connection with the annual report of China Expert Technology, Inc. (the Company) on Form 10-KSB for the year ended December 31, 2004, as filed with the Securities and Exchange Commission on the date hereof (the Report), Kung Sze Chau,
the Chief Executive Officer of the Company, hereby certifies, pursuant to Exchange Act Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.







/s/  King Sze Chau

Chief Executive Officer

Date:  March 14, 2005
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Accounting Standards Advisory Board

# AGENCY:

Federal Accounting Standards Advisory Board.

# ACTION:

Notice.

# SUMMARY:

Notice is hereby given that the Appointments Panel, a subcommittee of the Federal Accounting Standards Advisory Board (FASAB), will hold meetings on February 3, 19, and 20, 2025. The Appointments Panel makes recommendations regarding appointments for non-Federal member positions.

# FOR FURTHER INFORMATION CONTACT:

Ms. Monica R. Valentine, Executive Director, 441 G Street NW, Suite 1155, Washington, DC 20548, or call (202) 512-7350.

# SUPPLEMENTARY INFORMATION:

The meetings are closed to the public. The reason for the closure is that matters covered by 5 U.S.C. 552b(c)(2) and (6) will be discussed. Any such discussions will involve matters that relate solely to internal personnel rules and practices of the sponsor agencies and the disclosure of information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy.

                    Pursuant to section 10(d) of the Federal Advisory Committee Act (FACA), 5 U.S.C. 1009(d), portions of advisory committee meetings may be closed to the public where the head of the agency to which the advisory committee reports determines that such portion of such meeting may be closed to the public in accordance with subsection (c) of section 552b of title 5, United States Code. The determination shall be in writing and shall contain the reasons for the determination. A determination has been made in writing by the U.S. Government Accountability Office, the U.S. Department of the Treasury, and the Office of Management and Budget, as required by section 10(d) of FACA, that such portions of the meetings may be closed to the public in                           ( print page 7137)                        accordance with subsection (c) of section 552b of title 5, United States Code.                

*Authority:*31 U.S.C. 3511(d); Federal Advisory Committee Act, 5 U.S.C. 1001-1014.                

Dated: January 15, 2025.

Monica R. Valentine,

Executive Director.

[FR Doc. 2025-01321 Filed 1-17-25; 8:45 am]

BILLING CODE 1610-02-P
M.H., a Juvenile, Appellant, v. The STATE of Florida, Appellee.

No. 3D18-312

District Court of Appeal of Florida, Third District.

Opinion filed March 20, 2019.

Carlos J. Martinez, Public Defender, and Shannon Hemmendinger, Assistant Public Defender, for appellant.

Ashley Moody, Attorney General, and Kayla H. McNab, Assistant Attorney General, for appellee.

Before SALTER, SCALES, and MILLER, JJ.

PER CURIAM.

Affirmed. *See**Joseph v. State*, 868 So.2d 5, 8 (Fla. 4th DCA 2004) ("[The defendant] was not asked for his opinion of the detective's credibility. [He] was not required to choose between conceding the point or branding the detective as a liar. Asking whether another witness is 'wrong,' 'not accurate,' or 'mistaken' is very different from asking whether the witness is a liar.") (internal citations omitted); *U.S. v. Gaines*, 170 F.3d 72, 82 (1st Cir. 1999) ("The witness was not required to choose between conceding the point or branding another witness as a liar."); *U.S. v. Gaind*, 31 F.3d 73, 77 (2d Cir. 1994) ("Asking a witness whether a previous witness who gave conflicting testimony is 'mistaken' highlights the objective conflict without requiring the witness to condemn the prior witness a purveyor of deliberate falsehood, i.e., a 'liar.' ").
DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA

FOURTH DISTRICT

DEBORAH WHITMORE TEXTOR,

Appellant,

v.

SEAN HEYNIGER, et al.,

Appellees.

No. 4D22-2819

[July 6, 2023]

Appeal from the Circuit Court for the Fifteenth Judicial Circuit, Palm 

Beach County; Jamie Goodman, Judge; L.T. Case No. 502021CA004392.

Alan M. Burger of McDonald Hopkins LLC, West Palm Beach, for 

appellant. 

Eric C. Christu and Michael A. Munoz of Shutts & Bowen LLP, West 

Palm Beach, for appellees.

PER CURIAM.

Affirmed.

KLINGENSMITH, C.J., FORST and ARTAU, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
Case 3:05-cv-00202-M Document 80 Filed 01/19/06 Page 1 of 1 PageID 316
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Trade Commission

# AGENCY:

Federal Trade Commission.

# ACTION:

Annual notice of revision.

# SUMMARY:

The Federal Trade Commission announces the revised thresholds for interlocking directorates required by the 1990 amendment of section 8 of the Clayton Act.

# DATES:

January 22, 2025.

# FOR FURTHER INFORMATION CONTACT:

Christopher M. Grengs (202-326-2612), Bureau of Competition, Office of Policy and Coordination.

# SUPPLEMENTARY INFORMATION:

Section 8 prohibits, with certain exceptions, one person from serving as a director or officer of two competing corporations if two thresholds are met. Competitor corporations are covered by section 8 if each one has capital, surplus, and undivided profits aggregating more than $10,000,000, with the exception that no corporation is covered if the competitive sales of either corporation are less than $1,000,000. Section 8(a)(5) requires the Federal Trade Commission to revise those thresholds annually, based on the change in gross national product. The new thresholds, which take effect immediately, are $51,380,000 for section 8(a)(1), and $5,138,000 for section 8(a)(2)(A).

*Authority:*15 U.S.C. 19(a)(5).                

April J. Tabor,

Secretary.

[FR Doc. 2025-01513 Filed 1-21-25; 8:45 am]

BILLING CODE 6750-01-P
Casey James PARENTE, Appellant/Petitioner(s), v. Colonel Wayne BUNTON and State of Florida, Appellee/Respondent(s).

CASE NO.:2D19-1612

District Court of Appeal of Florida, Second District.

May 14, 2019

**FLORIDA DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
# C_2019399EN.01000501.xml

| 25.11.2019 | EN | Official Journal of the European Union | C 399/5 |
| --- | --- | --- | --- |

25.11.2019

EN

Official Journal of the European Union

C 399/5

---

Judgment of the Court (Sixth Chamber) of 18 September 2019 (request for a preliminary ruling from the Bundesfinanzhof — Germany) — Finanzamt Kyritz v Wolf-Henning Peters

(Case C-700/17) (1)

(Reference for a preliminary ruling - Taxation - Common system of value added tax (VAT) - Directive 2006/112/EC - Article 132(1)(b) and (c) - Exemptions - Hospital and medical care - Provision of medical care in the exercise of the medical and paramedical professions - No confidential relationship between the person providing the care and the patient)

(2019/C 399/05)

Language of the case: German

Referring court

Bundesfinanzhof

Parties to the main proceedings

Appellant in the appeal on a point of law: Finanzamt Kyritz

Respondent in the appeal on a point of law: Wolf-Henning Peters

Operative part of the judgment

| 1. | Article 132(1)(b) and (c) of Council Directive 2006/112/EC of 28 November 2006 on the common system of value added tax must be interpreted as meaning that the provision of medical care such as that at issue in the main proceedings, supplied by a medical specialist in clinical chemistry and laboratory diagnostics, is capable of falling within the scope of the exemption from VAT under Article 132(1)(c) of that directive, where it fails to meet all the conditions for the application of the exemption under Article 132(1)(b) of the directive; |
| --- | --- |

1.

Article 132(1)(b) and (c) of Council Directive 2006/112/EC of 28 November 2006 on the common system of value added tax must be interpreted as meaning that the provision of medical care such as that at issue in the main proceedings, supplied by a medical specialist in clinical chemistry and laboratory diagnostics, is capable of falling within the scope of the exemption from VAT under Article 132(1)(c) of that directive, where it fails to meet all the conditions for the application of the exemption under Article 132(1)(b) of the directive;

| 2. | Article 132(1)(c) of Council Directive 2006/112 must be interpreted as meaning that the exemption from VAT that it provides for is not subject to the condition that the medical care in question is supplied within the framework of a confidential relationship between the patient and the person providing the care. |
| --- | --- |

2.

Article 132(1)(c) of Council Directive 2006/112 must be interpreted as meaning that the exemption from VAT that it provides for is not subject to the condition that the medical care in question is supplied within the framework of a confidential relationship between the patient and the person providing the care.

---

(1)  OJ C 104, 19.3.2018.

---
Exhibit 12.1

GLOBALSANTAFE CORPORATION

STATEMENT SETTING FORTH DETAIL FOR COMPUTATION OF

RATIO OF EARNINGS TO FIXED CHARGES

(Millions
of dollars)



|                                              |  |                         |       |   |      |   |       |      |  |   |       |  
|--------------------------------------------- |  | ----------------------- | ----- | - | ---- | - | ----- | ---- |  | - | ----- | -
|                                              |  | Year Ended December 31, |      
|                                              |  | 2005                    |       |   | 2004 |   |       | 2003 | 
|Fixed charges:                                |  |                         |       |   |      |   |       |      |  |   |       |  
|Interest expense, gross                       |  | $                       | 41.3  |   |      | $ | 55.5  |      |  | $ | 67.5  |  
|Portion of rentals representative of interest |  |                         | 61.4  |   |      |   | 35.6  |      |  |   | 26.1  |  
|                                              |  |                         |       |   |      |   |       |      |  |   |       |  
|Total fixed charges                           |  | $                       | 102.7 |   |      | $ | 91.1  |      |  | $ | 93.6  |  
|                                              |  |                         |       |   |      |   |       |      |  |   |       |  
|Earnings before fixed charges:                |  |                         |       |   |      |   |       |      |  |   |       |  
|Income before income taxes                    |  | $                       | 486.0 |   |      | $ | 98.0  |      |  | $ | 129.2 |  
|Fixed charges                                 |  |                         | 102.7 |   |      |   | 91.1  |      |  |   | 93.6  |  
|Capitalized interest                          |  |                         | (38.1 | ) |      |   | (41.0 | )    |  |   | (34.9 | )
|Amortization of capitalized interest          |  |                         | 3.9   |   |      |   | 3.4   |      |  |   | 3.1   |  
|                                              |  |                         |       |   |      |   |       |      |  |   |       |  
|Total earnings before fixed charges           |  | $                       | 554.5 |   |      | $ | 151.5 |      |  | $ | 191.0 |  
|                                              |  |                         |       |   |      |   |       |      |  |   |       |  
|Ratio of earnings to fixed charges:           |  |                         |       |   |      |   |       |      |  |   |       |  
|Earnings before fixed charges                 |  | $                       | 554.5 |   |      | $ | 151.5 |      |  | $ | 191.0 |  
|Fixed charges                                 |  | $                       | 102.7 |   |      | $ | 91.1  |      |  | $ | 93.6  |  
|Ratio of earnings to fixed charges            |  |                         | 5.40  |   |      |   | 1.66  |      |  |   | 2.04  |  
|                                              |  |                         |       |   |      |   |       |      |  |   |       |
Altus Jermar LEE, Appellant/Petitioner(s), v. STATE of Florida, Appellee/Respondent(s).

CASE NO.: 2D18-2186

District Court of Appeal of Florida, Second District.

April 01, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Denied.
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

SHANE C. SMITH,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 385 MAL 2018

Petition for Allowance of Appeal from 

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 18th day of December, 2018, the Petition for Allowance of 

Appeal is GRANTED. The issue, as stated by Petitioner, is:

Can a person be convicted of possession of a firearm with 

altered manufacturer’s number under 18 Pa.C.S.A. § 6110.2 

where the evidence clearly shows that the registration number 

at issue is fully legible and identifiable despite some scratch 

marks?
**Exhibit
      32.1**





**CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO SECTION 906**


**OF
      THE SARBANES-OXLEY ACT OF 2002**








In
      connection with the Quarterly Report on Form 10-Q of PokerTek, Inc. (the
“Registrant”) for the period ending March 31, 2006, as filed with the Securities
      and Exchange Commission on the date hereof (the “Report”), I, Gehrig H. White,
      Chief Executive Officer of the Registrant, and I, Christopher Daniels, Chief
      Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. § 1350, as
      adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:





(1)  The
      Report fully complies with the requirements of section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)  The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the
      Registrant.




Date: May
                11,
                2006
              By:
              /s/ Gehrig
                H.
                WhiteGehrig
                  H. White
                Chief
                  Executive OfficerDate: May 11, 2006
              By:
              /s/ Christopher
                DanielsChristopher Daniels
                Chief FinancialOfficer


A
      signed
      copy of this written statement required by Section 906 has been provided to
      PokerTek, Inc. and will be retained by PokerTek, Inc. and furnished to the
      Securities and Exchange Commission or its staff upon
      request.
G.S., Appellant/Petitioner(s), v. DEPT. OF CHILDREN & FAMILIES, Appellee/Respondent(s).

CASE NO.: 2D19-0534

District Court of Appeal of Florida, Second District.

May 02, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
EXHIBIT
32.1





CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO


18
U.S.C. SECTION 1350 AND EXCHANGE ACT RULES 13a-14(b)
AND 15d-14(b)


(Section 906
of the Sarbanes-Oxley Act of 2002)





In
connection with the Quarterly Report of Innovative Card Technologies, Inc. (the
“Company”) on Form 10-Q for the period ending September 30, 2010, as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I,
Richard Nathan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my
knowledge and belief:





(1)
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and




(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of the operation of the
      Company.





Date:
November 19, 2010





/s/ Richard
      NathanChief
      Executive Officer
                Innovative
      Card Technologies, Inc





This
certification accompanies the Report pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by
the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes
of Section 18 of the Securities Exchange Act of 1934, as
amended.





A signed
original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
| a.   | the      Report fully complies with the requirements of Section 13(a) or 15(d) of      the Securities Exchange Act of 1934;and |
|----------------|--------------------------------------------------------------------------------------------------------------------------------|

| b.   | the      information contained in the Report fairly presents, in all material      respects, the financial condition and results of operations of the      Company. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                       | HemoBioTech,      Inc. |                                                                          |
|----------------------------|------------------------|-------------------------------------------------------------------------------|
|                       |                   |                                                                          |   |
| Date:      August 14, 2008 | By:                    | /s/ MARK      J. ROSENBLUM                                               |   |
|                       |                   | MARK      J. ROSENBLUM                                                        |   |
|                       |                   | CHIEF      FINANCIAL OFFICER(PRINCIPAL      FINANCIAL AND ACCOUNTING OFFICER) |   |
|                       |                   |                                                                          |   |